B. Riley Reiterates “Buy” Rating for DURECT (NASDAQ:DRRX)

DURECT (NASDAQ:DRRX)‘s stock had its “buy” rating restated by investment analysts at B. Riley in a note issued to investors on Monday, TipRanks reports. They currently have a $5.00 price objective on the specialty pharmaceutical company’s stock. B. Riley’s target price would suggest a potential upside of 115.52% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. BidaskClub cut shares of DURECT from a “buy” rating to a “hold” rating in a report on Saturday, May 30th. ValuEngine upgraded shares of DURECT from a “hold” rating to a “buy” rating in a research note on Tuesday, April 14th. Zacks Investment Research cut shares of DURECT from a “buy” rating to a “hold” rating in a research note on Friday, May 8th. Finally, HC Wainwright upped their price target on shares of DURECT from $5.50 to $6.00 and gave the stock a “buy” rating in a research note on Wednesday, May 27th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. DURECT presently has a consensus rating of “Buy” and an average target price of $4.12.

Shares of DRRX stock opened at $2.32 on Monday. DURECT has a 12 month low of $0.60 and a 12 month high of $3.95. The stock has a market cap of $480.26 million, a PE ratio of -19.33 and a beta of 2.20. The company has a current ratio of 2.57, a quick ratio of 2.43 and a debt-to-equity ratio of 1.75. The company’s fifty day moving average price is $2.40 and its 200-day moving average price is $2.13.

DURECT (NASDAQ:DRRX) last announced its earnings results on Monday, May 11th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.01). DURECT had a negative net margin of 82.94% and a negative return on equity of 114.36%. The business had revenue of $2.78 million for the quarter, compared to the consensus estimate of $4.74 million. On average, sell-side analysts forecast that DURECT will post -0.18 earnings per share for the current fiscal year.

In other DURECT news, VP Judy R. Joice sold 57,820 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $2.45, for a total value of $141,659.00. Following the completion of the transaction, the vice president now owns 67,611 shares of the company’s stock, valued at approximately $165,646.95. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Lp Bleichroeder sold 39,388 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $2.50, for a total value of $98,470.00. The disclosure for this sale can be found here. 10.20% of the stock is currently owned by insiders.

Large investors have recently modified their holdings of the business. BRYN MAWR TRUST Co purchased a new position in DURECT in the 1st quarter worth about $33,000. Private Advisor Group LLC bought a new position in shares of DURECT during the 1st quarter valued at approximately $36,000. Financial Consulate Inc. bought a new position in shares of DURECT during the 1st quarter valued at approximately $38,000. Alambic Investment Management L.P. grew its stake in shares of DURECT by 31.1% during the 1st quarter. Alambic Investment Management L.P. now owns 27,800 shares of the specialty pharmaceutical company’s stock valued at $43,000 after acquiring an additional 6,600 shares during the period. Finally, UBS Group AG grew its stake in shares of DURECT by 168.7% during the 4th quarter. UBS Group AG now owns 18,979 shares of the specialty pharmaceutical company’s stock valued at $72,000 after acquiring an additional 11,916 shares during the period. 49.93% of the stock is owned by institutional investors and hedge funds.

About DURECT

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand.

Further Reading: How a Put Option Works

Analyst Recommendations for DURECT (NASDAQ:DRRX)

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.